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Aims: To evaluate metastatic lesions within the radiation ﬁeld using repeated magnetic resonance
imaging (MRI) and to compare the imaging ﬁndings with pain response following radiotherapy (RT) in
patients with spinal metastases (SM) from breast cancer.
Material and methods: 32 Patients with SM from breast cancer admitted for fractionated RT were
included in this study. MRI examinations of the spine were scored for the extent of bone metastases,
epidural disease and the presence and severity of vertebral fractures. Clinical response was deﬁned
according to the updated international consensus on palliative RT endpoints.
Results: At 2 and 6 months after RT, 38% and 44% of the patients were classiﬁed as responders. None of
the patients developed motor deﬁcits. Importantly, a decrease in the intraspinal tumor volume after RT
was reported in all patients. Only 6% of the patients showed bone metastases progression within the RT
ﬁeld, whereas 60% of the patients showed disease progression outside the RT portals. 5 Patients
developed new fractures after RT, and fracture progression was observed in 21 of the 38 lesions (55%).
The pain response to RT did not correlate with the presence of vertebral body fracture before RT, fracture
progression or other recorded MRI features of metastatic lesions.
Conclusion: RT provided excellent local tumor control in patients with SM. Most patients beneﬁt from RT
even in cases of progressive vertebral fracture. Pain response was not associated with imaging ﬁndings
and MRI cannot be used to select patients at risk of not responding to RT.
& 2014 Elsevier GmbH. All rights reserved.
1. Introduction
External beam radiotherapy (RT) is a well-established and
efﬁcacious method of palliating painful bone metastases [1,2].
Patients with bone metastases are at high risk for skeletal-related
events such as pathologic fractures or spinal cord compression [3].
This may affect the pain response following RT and lower the
quality of life in these patients [4]. However, limited data exist on
the local disease control and the incidence of fractures after
conventional fractionated RT to the spine [2,4–8]. Furthermore,
the impact of fractures on pain response is essentially unknown.
Magnetic resonance imaging (MRI) is the modality of choice for
the diagnosis and follow-up of cancer patients with spinal
metastases (SM). Only a few studies have evaluated pain response
and imaging features after RT in patients with SM, and the ﬁndings
have been inconsistent [9–11]. Hence, it is important to determine
to what extent the RT response rate in SM is correlated with the
presence of skeletal complications such as fractures or compres-
sion syndromes. Thus, the aim of this study was to evaluate the
irradiated metastatic lesions and the rate of local tumor control
using repeated MRI and to compare the imaging ﬁndings with
pain response after RT in patients with SM from breast cancer.
2. Material and methods
2.1. Patients
All consecutive patients with symptomatic SM who were
admitted to our institution in 2007 and 2008 were considered
for inclusion in a prospective clinical study [12]. The current paper
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is a retrospective analysis of 32 patients (30 women and 2 men)
with SM from breast cancer who were part of the aforementioned
clinical study [12]. The inclusion criteria for the present study
were as follows: ﬁrst-time admittance for RT for SM from breast
cancer, no motor deﬁcit prior to RT, survival for more than
6 months after RT, available pre- and post-treatment MRI of the
vertebral column, age greater than 18 years and signed informed
consent. Post-treatment MRIs were conducted to evaluate local
disease progression and as a part of routine follow-up for systemic
disease status. All patients completed an MRI exam prior to RT and
an MRI exam after such treatment. Pretreatment MRIs were
performed within 2 months prior to RT. Post-treatment MRIs were
performed within 2–6 months of the RT. Patients with paraver-
tebral metastases with direct extension into vertebral bodies and
patients with leptomeningeal or intramedullary metastases were
not eligible.
All patients were interviewed prior to and at 2 and 6 months
after RT using a validated Norwegian version of the Brief Pain
Inventory form [12,13]. The worst, average and least pain experi-
ences during the previous 24 h and the current pain level were
recorded using a 10-point scale. The worst pain experience was
used as the principal outcome measure. Details on opioid con-
sumption during the previous 24 h, including the drug name, daily
dose and administration route, were recorded. All opioids were
converted into the oral morphine-equivalent dose (OMED).
Clinical response to treatment was deﬁned according to the
updated International Bone Metastases Consensus Working Party
palliative RT endpoints [1]. A complete response (CR) was deﬁned
as a pain score of 0 with no increase in the OMED. A partial
response (PR) was deﬁned either as a pain reduction of 2 or more
points measured on a 10-point scale or an OMED reduction of 25%
or more. Pain progression (PP) was deﬁned as a pain increase of
2 or more points or an increase in the OMED of 25% or more.
Patients not classiﬁed as having CR, PR or PP were deﬁned as
having an indeterminate response (IR). Patients with either CR or
PR were deﬁned as responders, whereas patients with either IR or
PP were deﬁned as non-responders [1].
2.2. MRI studies
64 MRI studies were performed in 32 patients. Entire spine MRI
examinations were available in all but 2 patients. All images were
retrospectively reviewed by one radiologist (MDS) who was
blinded to the clinical records. Bone metastases were categorized
as either diffuse inﬁltration of the bone marrow or focal lesions
[14,15]. The metastasis with the largest diameter or that was most
suitable to measure was recorded as the target lesion. To avoid
partial volume artifacts, only lesions with a diameter equal to or
greater than 8 mm were considered measurable (2 slice thick-
ness) [15].
Other recorded features included tumor-conditioned spinal
canal stenosis (SCS), compression of the spinal cord, cauda equina
and nerve roots. SCS was deﬁned as a narrowing of the cross-
sectional area of the spinal canal by a soft tissue tumor extension,
bone fragments or both. Compression of the spinal cord was
deﬁned as a deviation or indentation of the spinal cord by an
epidural tumor or bone fragments. Compression of the cauda
equina was deﬁned as an obliteration of the cerebrospinal ﬂuid in
the dural sac at the affected level. Nerve root compression was
deﬁned as contact between the tumor masses or bone fragments
and the spinal nerves in the recess or intervertebral foramen [16].
Vertebral body fractures were recorded both prior to and after
RT. A difference of Z2 mm (2pixel spacing) between the pre-
and post-treatment vertebral height was recorded as fracture
progression. Additional studied features included the level of the
fractures, the percentage of vertebral height loss, and the percen-
tage of metastatic vertebral body involvement.
The appearance of new lesions, a change in the metastatic
pattern from focal to diffuse or at least a 20% increase in the largest
diameter of the target lesions after RT was deﬁned as progression.
The disappearance of lesions or a reduction at least 30% in the
diameters of the target lesions was deﬁned as a response [14,15].
The radiological response of spinal lesions was evaluated both
inside and outside the RT portals. To assess the epidural tumor
volume, a cross-sectional area of the spinal canal was measured at
the affected level and compared with the cross-sectional area at
the same level on post-treatment images.
2.3. Statistical analyses
Data were analyzed using IBM SPSSc Statistics version 21 (IBM,
New York, NY, USA). Descriptive statistics including frequency
distributions and percentages were used to describe the patient
population. Chi-squared tests were used to compare proportions.
All reported p values were based on 2-sided tests; po0.05 was
considered statistically signiﬁcant.
2.4. Ethics
This study was approved by the Regional Ethics Committee,
and written informed consent was obtained from all patients.
3. Results
3.1. Patients
The mean patient age at the start of treatment was 58 years
(range 82–35). All patients received a radiation dose of 30 Gy
delivered in 10 fractions within 2 weeks. RT was given in
combination with ongoing chemotherapy (4 patients), hormone
treatment (22 patients), bisphosphonates (7 patients) or corticos-
teroids (7 patients). Importantly, none of the patients developed
neurological symptoms at the 2- or 6-month follow-up. All
patients were ambulatory prior to and at 2 months after RT; at
6 months after RT, 1 of the 32 patients was non-ambulatory due to
poor performance status related to general disease progression.
The mean pain scores were 4.3, 3.9 and 3.7 at baseline,
2 months and 6 months after RT, respectively. The corresponding
mean OMED values were 100, 96 and 145 mg, respectively. At
2 and 6 months after RT, 12 patients (38%) and 14 patients (44%)
were classiﬁed as responders. Age, ongoing chemotherapy, hor-
mone therapy and the use of bisphosphonates were not associated
with the pain response; however, patients younger than 65 years
of age showed a better response than did the older patients (11 vs.
1 responder at 2 months).
3.2. MRI ﬁndings
Pretreatment MRIs were obtained within 1–47 days (mean
16 days) prior to RT. Post-treatment MRIs were obtained within
61–180 days (mean 103 days) after the completion of RT. The
recorded MRI ﬁndings are presented in Table 1.
On the pretreatment MRIs, 23 patients had focal bony metastases
and 9 patients had diffuse metastatic bone marrow inﬁltration. SCS
was noted in 21 patients. For all but 1 patient, SCS was caused by
both the epidural tumor and fracture. Compression of the spinal
cord/cauda equina was present in 8 patients. Fractures were noted in
22 patients (13 patients at a single spinal level and in 9 patients at
multiple levels). In total, 38 fractures were evaluated in 22 patients.
All fractures were pathological, tumor-induced fractures.
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On the post-treatment MRIs, 2 of the 32 (6%) patients showed a
progression of bony disease within the RT ﬁeld and 19 of the 32
patients (60%) showed a progression of bony disease outside the
RT ﬁeld. None of the patients demonstrated a decrease of more
than 30% in the size of target lesions. A decreased epidural tumor
volume was observed in all patients (Fig. 1). Only 2 of the 21
patients with pretreatment SCS and fracture showed an increase in
the grade of SCS due to fracture progression. The compression
persisted after RT in 3 of the 8 patients with pretreatment
compression of the spinal cord or cauda equina. Progression of
the vertebral fracture was observed in 21 of the 38 lesions (55%) in
17 patients. A total of 5 patients (15%) developed new fractures
after RT; 1 patient had a benign (radiation-induced) fracture and
4 patients had malignant (tumor-induced) fractures.
3.3. MRI ﬁndings and pain response to RT
The distribution of pre- and post-treatment MRI ﬁndings
among responders and non-responders is presented in Table 2.
Patients with advanced disease such as large metastases prior to
RT (475% of vertebral body involvement) or diffuse inﬁltration of
bone marrow, and patients with compression of the medulla
spinalis/cauda equina tended to be non-responders more fre-
quently; however, these data did not reach statistical signiﬁcance.
The pain response was not associated with SCS, nerve root
compression or progressive metastatic disease outside or within
the RT ﬁeld. The pain response was not associated with the
presence of vertebral fractures before RT, fracture progression,
the grade of vertebral body height loss or new fractures after RT.
Table 1
Registered MRI features (n¼32).
MRI ﬁndings n %
Pre-treatment MRI studies
1. Bone metastases
Focal lesions 23 72
Diffuse inﬁltration 9 28
2. Spinal epidural disease
Spinal canal stenosis 21 66
Compression of the spinal cord or cauda equina 8 25
Nerve root compression 15 47
3. Fractures
Single level 13 41
Multiple levels 9 28
Follow-up MRI studies
1. Progressive disease (bone marrow)
Inside the RT ﬁeld 2 6
Outside the RT ﬁeld 19 59
Unable to obtaina 4 13
2. Spinal epidural disease
Decreased spinal canal stenosis grade 18 56
Increased spinal canal stenosis grade 2 6
Unable to estimateb 1 3
Compression of the spinal cord or cauda equina 3 9
Nerve root compression 8 25
Fracture progression in patients with spinal canal stenosis 11 34
3. Fractures
New fractures 5 16
Fracture progression 17 53
a Incomplete examination (only lumbar spine, n¼2) and diffuse inﬁltration of
bone marrow (n¼2).
b Suboptimal image quality.
Fig. 1. Spinal metastases from a breast carcinoma in a 74-year-old woman prior to (A–C) and after radiation therapy (D–F). Sagittal T1-weighted, STIR and transversal T2-
weighted MR images of the spine show pathological vertebral fractures, tumor-conditioned spinal canal stenosis and compression of the spinal cord at the Th11 level. After
treatment, the cross-sectional area of the spinal canal is improved signiﬁcantly despite fracture progression at Th11 and increased kyphosis.
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4. Discussion
This study investigated the relationship between MRI features
and the pain response after fractionated RT in a cohort of patients
with breast cancer metastases to the spine.
In our series, fracture progression was noted in 53% of the
lesions and 5 patients presented with new fractures after RT.
Previous studies reported on the rate of pathologic fractures after
single or multifraction RT; however, they did not stratify between
spine and other locations in the skeleton [2,4–7]. Neither the
impact of vertebral fractures upon treatment response nor the risk
of fracture in different radiation regimens is assessed properly and
need to be examined. More pathological fractures seemingly
occurred after single fraction RT than after multifraction therapy,
but the absolute percentage was low [2,6,7]. In general, dose
prescription and fractionation should be adjusted to the thera-
peutic goal and patient prognosis. Patients included in this study
had a relatively long expected survival. Consequently, local disease
stabilization and prevention of neurological deﬁcits were the main
therapeutic goals, and all patients beneﬁted from the fractionated
regimen [17].
Vertebral fractures at the initiation of RT were present in 69% of
the patients in our series. This percentage is also higher than in
previous reports that included patients with various cancer
diagnoses [9,10], and this difference could reﬂect a higher inci-
dence of vertebral body fractures in patients with breast cancer
[18] and tumor biology with a tendency toward osteolytic metas-
tases [19].
The presence of signiﬁcant bone destruction has been impli-
cated as an indicator of poor prognosis for treatment outcomes
[10]; however, the results of previous studies are inconsistent
[9–11]. Zelefsky et al. showed that patients with compression
fractures with greater than 50% of vertebral body height loss were
less likely to show favorable clinical and radiological responses to
RT [10], whereas Maranzano and Latini showed that neither the
presence of vertebral body collapse nor the number of spinal
compression sites inﬂuenced survival or the response to RT [11].
The study by Mitera et al. implied that the pain response after RT
did not differ depending on the presence of a pathological fracture
or any other imaging features related to the degree of tumor
involvement [9]. Our results are to some extent consistent with
these reports. Patients with widespread bony metastases (diffuse
inﬁltration of bone marrow or large metastases) and patients with
spinal cord compression prior to RT frequently present with more
aggressive disease and, according to our data, tend to show poorer
responses to RT, not statistically signiﬁcant. The pain response rate
to RT was similar in patients with vertebral fractures, fracture
progression or other recorded MRI ﬁndings.
Importantly, the epidural tumor volume was reduced in all
patients, and all but 3 patients showed an increase in the cross-
sectional area of the spinal canal despite fracture progression.
Additionally, there was excellent control of bone-only metastases;
only 6% of the patients showed disease progression within the RT
ﬁeld, compared with 60% of the patients with progression of SM
outside the RT ﬁeld. The standard treatment protocol in patients
included in this study involved a single posterior–anterior (PA)
ﬁeld. Using single PA beam treatment is common in the palliative
irradiation of SM. However, dose coverage and heterogeneity may
affect the treatment outcome, since distribution decreases in the
anterior half of the vertebral body and anterior to the vertebral
column [20]. This may partly explain the progression of bone
lesions in 1 of 2 patients with progressive disease within the
RT ﬁeld.
The major limitation of this study remains restricted number of
patients. Hence, the results should be veriﬁed in larger studies.
Consequently, precisely predicting treatment response and identi-
fying statistically signiﬁcant groups is not feasible in small sam-
ples. Additional limitations include relatively broad time variations
in the post-treatment MRI examinations – as a consequence of
repeated MRIs not being part of the prospective study design [12].
In conclusion, RT provided effective local control of spinal
metastatic disease in most patients, and our results indicate that
most patients with SM beneﬁt from RT even in cases of progressive
vertebral fracture. The pain response rate did not correlate with
Table 2
Recorded MRI ﬁndings and pain response at 2 and 6 months after RT (n¼32).
MRI ﬁndings Pain response at 2 months Pain response at 6 months
Non-responders Responders Non-responders Responders
Compression of medulla spinalis/cauda equinaa Yes (n¼8) 7 1 6 2
No (n¼23) 13 10 12 11
Nerve root compressionb Yes (n¼15) 9 6 7 8
No (n¼14) 9 5 9 5
Progression outside the RT ﬁeldc Yes (n¼19) 11 8 11 8
No (n¼9) 7 2 5 4
Progression inside the RT ﬁeldd Yes (n¼2) 1 1 1 1
No (n¼28) 17 11 16 12
Fracture progression Yes (n¼17) 11 6 9 8
No (n¼15) 9 6 9 6
New fractures Yes (n¼5) 4 1 3 2
No (n¼27) 16 11 15 12
Diffuse inﬁltration of bone marrow Yes (n¼9) 8 1 7 2
No (n¼23) 12 11 11 12
Large focal metastases (475% of vertebral body involvement) Yes (n¼24) 17 7 14 10
No (n¼8) 3 5 4 4
a Unable to estimate in 1 patient due to suboptimal image quality.
b Uncertain ﬁndings in 3 patients due to image quality.
c Unable to obtain in 4 patients due to incomplete examination (only lumbar spine, n¼2) and diffuse inﬁltration of bone marrow (n¼2).
d Unable to obtain in 2 patients due to diffuse metastatic inﬁltration of bone marrow.
M.D. Switlyk et al. / Journal of Bone Oncology 3 (2014) 5–98
any imaging ﬁndings; thus, performing MRI as a part of routine
follow-up after RT is likely unnecessary for most patients except
for those in whom clinical disease progression is suspected and for
those with new symptoms.
Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
Acknowledgments
The authors would like to thank Dr. Bjørn Naume, and Dr. Erik
Løkkevik from the Department of Clinical Oncology, the Norwe-
gian Radium Hospital for their helpful comments. This study was
supported by grants from the Norwegian Radium Hospital Foun-
dation, the Norwegian Cancer Society and the Regional Health
Authority of South-Eastern Norway.
References
[1] Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the
international consensus on palliative radiotherapy endpoints for future clinical
trials in bone metastases. Int J Radiat Oncol Biol Phys 2012;82:1730–7.
[2] Chow E, Khan LM, Bruland OS. Radiotherapy of skeletal metastases. In:
Rosen CJ, editor. Primer on the metabolic diseases and disorders of mineral
metabolism. Washington (DC): ASBMR; 2013. p. 754–9.
[3] Lipton A. Clinical features of metastatic bone disease. In: Coleman RE,
Abrahamsson PA, Hadji P, editors. Handbook of cancer-related bone disease.
Bristol: Bio Scientiﬁca; 2012. p. 59–71.
[4] Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, et al.
Randomized trial of short- versus long-course radiotherapy for palliation of
painful bone metastases. J Natl Cancer Inst 2005;97:798–804.
[5] Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, et al. Long
term follow-up of cancer patients receiving radiotherapy for bone metastases:
results from a randomized multicentre trial. Radiother Oncol 2009;91:261–6.
[6] Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J,
et al. The effect of a single dose fraction compared to multiple fractions on
painful bone metastases: a global analysis of the Dutch Bone Metastasis Study.
Radiother Oncol 1999;52:101–9.
[7] Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone
pain: single fraction versus multifraction radiotherapy—a systematic review of
randomized trials. Clin Oncol (R Coll Radiol) 2003;15:345–52.
[8] van der Linden YM, Steenland E, van Houwelingen HC, Post WJ, Oei B,
Marijnen CA, et al. Patients with a favourable prognosis are equally palliated
with single and multiple fraction radiotherapy: results on survival in the
Dutch Bone Metastasis Study. Radiother Oncol 2006;78:245–53.
[9] Mitera G, Probyn L, Ford M, Donovan A, Rubenstein J, Finkelstein J, et al.
Correlation of computed tomography imaging features with pain response in
patients with spine metastases after radiation therapy. Int J Radiat Oncol Biol
Phys 2011;81:827–30.
[10] Zelefsky MJ, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY. Spinal epidural
tumor in patients with prostate cancer. Clinical and radiographic predictors of
response to radiation therapy. Cancer 1992;70:2319–25.
[11] Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in
metastatic spinal cord compression: ﬁnal results from a prospective trial. Int J
Radiat Oncol Biol Phys 1995;32:959–67.
[12] Zaikova O, Fossa SD, Kongsgaard U, Kvaloy S, Giercksky KE, Skjeldal S. Pain
after palliative radiotherapy for spine metastases. Clin Oncol (R Coll Radiol)
2010;22:828–36.
[13] Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The
Norwegian brief pain inventory questionnaire: translation and validation in
cancer pain patients. J Pain Symptom Manage 2002;24:517–25.
[14] Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE.
Magnetic resonance imaging of the axial skeleton enables objective measure-
ment of tumor response on prostate cancer bone metastases. Prostate
2005;65:178–87.
[15] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer 2009;45:228–47.
[16] Switlyk MD, Hole KH, Skjeldal S, Hald JK, Knutstad K, Seierstad T, et al. MRI
and neurological ﬁndings in patients with spinal metastases. Acta Radiol
2012;53:1164–72.
[17] Souchon R, Wenz F, Sedlmayer F, Budach W, Dunst J, Feyer P, et al. DEGRO
practice guidelines for palliative radiotherapy of metastatic breast cancer:
bone metastases and metastatic spinal cord compression (MSCC). Strahlenther
Onkol 2009;185:417–24.
[18] Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high
incidence of vertebral fracture in women with breast cancer. Br J Cancer
1999;79:1179–81.
[19] Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of
osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia
2005;10:169–80.
[20] Andic F, Baz Cifci S, Ors Y, Niang U, Dirier A, Adli M. A dosimetric comparison
of different treatment plans of palliative spinal bone irradiation: analysis of
dose coverage with respect to ICRU 50 report. J Exp Clin Cancer Res 2009;28:2.
M.D. Switlyk et al. / Journal of Bone Oncology 3 (2014) 5–9 9
